Troubleshooting Biomarker Development Strategies
Add bookmarkTroubleshooting Biomarker Development Strategies
Add bookmark
In this Pharma IQ interview Kristof Vercruysse, Director Clinical Operations at Ablynx, speaks to Dr. Gabriele Dallmann, CEO of Pharmatching GmbH, about innovation in phase I clinical development and optimisation of biomarker development strategies. Vercruysse discusses biomarker development strategies, which are of great importance for every clinical trial – he identifies the critical success factors, the optimum time to start biomarker development and how it is decided which clinical development programmes to use them for. Vercruysse then gives some real life examples of how a biomarker has saved time, cost or helped to make a go/no-go decision.
[inlinead]
Tags:
Kristof Vercruysse
Ablynx
Gabriele Dallmann
Pharmatching
biomarkers
Biomarker
biomarker development
phase one clinical
Clinical Trials
phase one clinical trials
phase 1
phase I clinical development
